These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 10716717)

  • 1. Synthesis and antitumor activity of an inhibitor of fatty acid synthase.
    Kuhajda FP; Pizer ES; Li JN; Mani NS; Frehywot GL; Townsend CA
    Proc Natl Acad Sci U S A; 2000 Mar; 97(7):3450-4. PubMed ID: 10716717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatty acid synthase inhibitors cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma A-375 cells.
    Ho TS; Ho YP; Wong WY; Chi-Ming Chiu L; Wong YS; Eng-Choon Ooi V
    Biomed Pharmacother; 2007 Oct; 61(9):578-87. PubMed ID: 17904792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy.
    Rae C; Haberkorn U; Babich JW; Mairs RJ
    Radiat Res; 2015 Nov; 184(5):482-93. PubMed ID: 26484401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism.
    Landree LE; Hanlon AL; Strong DW; Rumbaugh G; Miller IM; Thupari JN; Connolly EC; Huganir RL; Richardson C; Witters LA; Kuhajda FP; Ronnett GV
    J Biol Chem; 2004 Jan; 279(5):3817-27. PubMed ID: 14615481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the inactivation of rat fatty acid synthase by C75: inhibition of partial reactions and protection by substrates.
    Rendina AR; Cheng D
    Biochem J; 2005 Jun; 388(Pt 3):895-903. PubMed ID: 15715522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice.
    Alli PM; Pinn ML; Jaffee EM; McFadden JM; Kuhajda FP
    Oncogene; 2005 Jan; 24(1):39-46. PubMed ID: 15489885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth arrest induced by C75, A fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma.
    Gao Y; Lin LP; Zhu CH; Chen Y; Hou YT; Ding J
    Cancer Biol Ther; 2006 Aug; 5(8):978-85. PubMed ID: 16855382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells.
    Wang HQ; Altomare DA; Skele KL; Poulikakos PI; Kuhajda FP; Di Cristofano A; Testa JR
    Oncogene; 2005 May; 24(22):3574-82. PubMed ID: 15806173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
    Menendez JA; Lupu R
    Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity.
    Thupari JN; Landree LE; Ronnett GV; Kuhajda FP
    Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9498-502. PubMed ID: 12060712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells.
    Zhou W; Simpson PJ; McFadden JM; Townsend CA; Medghalchi SM; Vadlamudi A; Pinn ML; Ronnett GV; Kuhajda FP
    Cancer Res; 2003 Nov; 63(21):7330-7. PubMed ID: 14612531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of fatty acid synthase is protective in pulmonary hypertension.
    Singh N; Manhas A; Kaur G; Jagavelu K; Hanif K
    Br J Pharmacol; 2016 Jun; 173(12):2030-45. PubMed ID: 27061087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
    Menendez JA; Vellon L; Mehmi I; Oza BP; Ropero S; Colomer R; Lupu R
    Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10715-20. PubMed ID: 15235125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-methylene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid (C75), an inhibitor of fatty-acid synthase, suppresses the mitochondrial fatty acid synthesis pathway and impairs mitochondrial function.
    Chen C; Han X; Zou X; Li Y; Yang L; Cao K; Xu J; Long J; Liu J; Feng Z
    J Biol Chem; 2014 Jun; 289(24):17184-94. PubMed ID: 24784139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of C75, an inhibitor of fatty acid synthase, on sleep and metabolism in mice.
    Pellinen J; Szentirmai É
    PLoS One; 2012; 7(2):e30651. PubMed ID: 22348016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG-PET for pharmacodynamic assessment of the fatty acid synthase inhibitor C75 in an experimental model of lung cancer.
    Lee JS; Orita H; Gabrielson K; Alvey S; Hagemann RL; Kuhajda FP; Gabrielson E; Pomper MG
    Pharm Res; 2007 Jun; 24(6):1202-7. PubMed ID: 17404812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anorexigenic fatty acid synthase inhibitor, C75, is a nonspecific neuronal activator.
    Takahashi KA; Smart JL; Liu H; Cone RD
    Endocrinology; 2004 Jan; 145(1):184-93. PubMed ID: 14512433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different fatty acid metabolism effects of (-)-epigallocatechin-3-gallate and C75 in adenocarcinoma lung cancer.
    Relat J; Blancafort A; Oliveras G; Cufí S; Haro D; Marrero PF; Puig T
    BMC Cancer; 2012 Jul; 12():280. PubMed ID: 22769244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of central and peripheral administration of C75 on food intake, body weight, and conditioned taste aversion.
    Clegg DJ; Wortman MD; Benoit SC; McOsker CC; Seeley RJ
    Diabetes; 2002 Nov; 51(11):3196-201. PubMed ID: 12401710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.